No, the herbal trial findings do not change acne care yet for adults with persistent acne. Standard daily treatment and long-term maintenance remain the practical path. Kularis is an oral herbal capsule with Commiphora wightii (guggul) and Amorphophallus konjac extracts. The National Library of Medicine PubMed record describes a 12-week randomized, double-blind, placebo-controlled trial in 100 men and women aged 18-40 with mild-to-severe acne, taking one capsule daily PubMed trial record.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the 12-week trial test?
- How strong were the results?
- Why do guidelines still favor standard care?
- What should adults with stubborn acne do now?
What did the 12-week trial test?
The study tested one daily herbal capsule against placebo for 12 weeks. It enrolled adults with mild-to-severe acne vulgaris, a common clogged-pore condition with blackheads, pimples, and tender red lumps. The design was proof-of-concept, not long-term care research.
It ran at a single center, enrolled 100 patients, and had no direct comparison with standard acne drugs. There was also no long-term follow-up after week 12. That gap matters for adults whose acne clears and then returns over months.
How strong were the results?
The active group had much higher Investigator Global Assessment success than placebo. Investigator Global Assessment is a doctor rating of overall acne clear or almost-clear status. Lesion counts also fell sharply for both inflamed pimples and non-inflamed blackheads and whiteheads.
The reported odds ratio for treatment success was 7.88, with very small p-values. Short-trial gains do not prove lasting control. Other herbal acne reviews also report fewer lesions without severe events in short trials, yet weak methods, varied formulas, varied scales, and brief study periods block firm safety and efficacy claims.
Why do guidelines still favor standard care?
The American Academy of Dermatology 2024 acne guidelines strongly recommend topical benzoyl peroxide, topical retinoids, topical or oral antibiotics and oral doxycycline, plus isotretinoin for severe disease, according to the Academy update American Academy of Dermatology update. They do not list an herbal supplement as standard care. Cochrane reached a similar caution for complementary options.
Its review found only low-quality evidence from single trials for selected options and no support for herbal medicine for acne vulgaris. For persistent adult acne, maintenance is the key difference. A 12-week result without a drug comparison and without months-long follow-up cannot replace treatments tested for ongoing use and relapse prevention.
What should adults with stubborn acne do now?
Do not swap a working retinoid, benzoyl peroxide, hormonal treatment, or isotretinoin plan for an herbal capsule yet. Persistent acne often needs steady use, dose changes, and relapse planning.
Herbal products sold as dietary supplements do not get FDA premarket approval for safety, effectiveness, or labeling, the agency explains in its FDA consumer guide on dietary supplements. Makers carry the main responsibility, while the FDA acts mainly after sale. Ask a clinician first about these points: Bring your product label and full drug and supplement list to that visit.
- liver risk, contamination risk, and drug interactions
- label accuracy, dose, and what "natural" does not guarantee
- how to track lesions, irritation, and missed doses for 8-12 weeks
- when to return if breakouts, scarring, dark marks, or mood changes worsen
You Might Also Like
- The 2026 Trial of Phyllanthus Emblica and Tinospora for Acne: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Herbal Acne Trial Safety and Evidence Limits in 2026: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Herbal Acne Trial Safety and Evidence Limits in 2026: How Adults With Persistent Acne Can Avoid Overreading the Headline